Navigation Links
Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19

SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced that it will be attending the 117th Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans, November 16-19 (Booth #5058). Imprimis' presence at this conference is primarily to continue the pre-launch assessments of two of its proprietary ophthalmic sterile injectable compounded formulations, which Imprimis expects to make available to the ophthalmology community in 2014.

Imprimis will also be hosting two events, during which they will be soliciting feedback from the ophthalmology community regarding the utility and commercialization potential of its proprietary ophthalmic compounded formulations.

To schedule meetings with Imprimis or to attend an Imprimis sponsored event, please contact Forest Flodin, Director of Corporate Development, at


Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company focused on the commercial development of novel drug formulations and proprietary drug delivery vehicles.  Imprimis believes in the power of the clinical interaction of one patient, one physician and one pharmacist to build novel therapeutic approaches that have broad market appeal.  Drug formulations created by pharmacists and physicians for a specific patient's use are investigated using through a proprietary and rigorous evaluation process, the Asset Review Methodology (ARM™), in order to assess potential for commercialization. Following this evaluation process, including clinical development, the company may choose to pursue FDA approval through the FDA's Section 505(b)(2) development pathway, or selectively make its treatment options available to the market through pharmacy compounding.  In addition, Imprimis expects to seek partnerships with wholesalers in order to make its drug delivery technologies available to compounding pharmacies across North America.  The company's current focus is in the Ophthalmology, Wound Management, Urology and Pain therapeutic areas.


This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Imprimis' results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Imprimis' ability to enter into licensing arrangements with pharmacies, physicians and healthcare organizations or to otherwise commercialize its formulations, its ability to obtain intellectual property protection for its assets, the success of additional research and development activities related to its formulations, its ability to accurately estimate its expenses and cash burn, its ability to raise additional funds, its ability to acquire, develop, commercialize or market new formulations and to enter into strategic alliances and transactions,  the projected size of the potential market for our product candidates, unexpected new data, safety and technical issues, regulatory and market developments impacting compounding pharmacies, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no  obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

For Media Inquiries:

Contact: Arielle Sklar or Robert Zito


For Investor Inquiries:

BPC Financial Marketing

Contact: John Baldissera


SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
2. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
3. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
4. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
5. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
6. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
7. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
8. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
9. Imprimis Announces Key Leadership Appointments
10. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
11. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
Post Your Comments:
(Date:11/30/2015)... TOKYO , 1 décembre 2015 ... plus grande exposition et conférence d,Asie ... médicaux et sur l,industrie manufacturière, se ... du 20 au 22 avril ... - Photo - ...
(Date:11/30/2015)... December 1, 2015 ... adds "Endometriosis - Pipeline Review, H2 2015" ... on therapeutic pipeline of Endometriosis and helps ... counter strategies to gain competitive advantage. It ... and MOAs to produce first-in-class and best-in-class ...
(Date:11/30/2015)... , Nov. 30, 2015  DURECT Corporation ... Matt Hogan , Chief Financial Officer, ... Conference on Tuesday, December 8 at 2:45 ... held at the Westin Grand Central Hotel ... available for one-on-one meetings at this conference; ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... Charlotte, NC (PRWEB) , ... December 01, 2015 ... ... NHS Foundation Trust on receiving the 2015 HSJ Acute Sector Innovation Award on ... of improving the patient care experience, and propose exciting enhancements to the medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Third Molar ... that it has officially launched a sleek, mobile-ready and user-centric redesigned website. , ... new website clearly outlines the benefits that its SEO services provide to dentists ...
(Date:11/30/2015)... NC (PRWEB) , ... November 30, 2015 , ... Trevor ... corporate support as they play for the chance to represent the United States. This ... the opportunity to be a part of their journey in addition to offering corporate ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Christina Colon as a 2015-2016 inductee into its ... for leadership in pharmacy. NAPW is the nation’s leading networking organization exclusively for ...
Breaking Medicine News(10 mins):